和邦生物：预计2025年度归属于上市公司股东的净利润将出现亏损

Group 1 - The core point of the article is that Hebang Biotechnology (603077.SH) has announced an expected net loss attributable to shareholders for the fiscal year 2025, primarily due to anticipated asset impairment provisions [1] Group 2 - The company’s financial department has conducted preliminary calculations indicating the projected loss [1]